Pathway analysis of genes affected by genomic anomalies also revealed enrichment of PIK3CA-AKT pathway which suggests potential therapeutic benefit of targeting PIK3CA in ESCC (Figure 6). This evidence concerns the gene AKT1 and esophageal squamous cell carcinoma.